Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma (Q46569297)

23 December 2017

title

Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma (English)

1 reference

23 December 2017

1 reference

Victor A Levin

1

1 reference

23 December 2017

Nancy D Mendelssohn

2

1 reference

23 December 2017

James Chan

3

1 reference

23 December 2017

Mady C Stovall

4

1 reference

23 December 2017

Scott J Peak

5

1 reference

23 December 2017

Jennie L Yee

6

1 reference

23 December 2017

Rita L Hui

7

1 reference

23 December 2017

David M Chen

8

1 reference

23 December 2017

publication date

11 January 2015

1 reference

23 December 2017

Journal of Neuro-Oncology

published in

1 reference

23 December 2017

volume

122

1 reference

23 December 2017

issue

1

1 reference

23 December 2017

page(s)

145-150

1 reference

23 December 2017

https://scigraph.springernature.com/pub.10.1007/s11060-014-1693-x

exact match

0 references

cites work

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Effect of bevacizumab on radiation necrosis of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Bevacizumab reverses cerebral radiation necrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Bevacizumab and recurrent malignant gliomas: a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

A generalized Wilcoxon test for comparing arbitrarily singly-censored samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Evaluation of malignant glioma patients during the postirradiation period

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Pseudoprogression in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Pseudoprogression and pseudoresponse in the treatment of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Pseudoprogression and pseudoresponse: challenges in brain tumor imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

Use of chemotherapy within the last 14 days of life in patients treated at a comprehensive cancer center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1693-X

A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES

21 January 2018

1 reference

12 December 2020

Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors.

1 reference

12 December 2020

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

12 December 2020

Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis

1 reference

12 December 2020

10.1007/S11060-014-1693-X

Identifiers

DOI

1 reference

23 December 2017

release_5sia5pw4qbefhhd5sdmw7iwkgi

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5sia5pw4qbefhhd5sdmw7iwkgi

24 November 2022

mapped directly with Wikidata item

1 reference

23 December 2017